ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Media centre

Media centre

Welcome to our media centre

You can contact the Press Office at PressOffice@abpi.org.uk or +44 (0) 20 7747 7147 (24hrs)

All News

NEWS

ABPI response to NHS Commercial Framework

23 Feb 2021

The NHS Commercial Framework for New Medicines has been published.

ABPI response to EU data adequacy decision

19 Feb 2021

The European Commission has issued a positive preliminary data adequacy decision for the UK which will allow data to continue to flow freely from the EU to the UK.

ABPI response to Life Science Competitiveness Indicators

15 Feb 2021

The government has published new data on the life science sector in the UK and other countries.

All blog posts

BLOG

There’s nothing we can’t do or achieve, but people with thalassaemia need understanding and support

17 Feb 2021

Thalassaemia major is a serious, genetic blood disorder. Roanna Maharaj was diagnosed with a severe form of the disease as a baby in the Caribbean. This is her story.

Evolving the UK health system to support innovation for the rare disease community

17 Feb 2021

Nicola Redfern, General Manager of bluebird bio in the UK, describes the commercial challenges for rare disease medicines in the UK and reflects on the opportunities of gene therapies. 

It’s never been more important to tell the great story of vaccines

11 Nov 2020

ABPI Chief Executive talks about the importance of vaccines, as ABPI launches its new campaign, #ValuingVaccines. 

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.